Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10037243 | 0.85 | KIF11 (0.64) | KIF11 | |
| SCHEMBL8504226 | 0.83 | KIF11 (0.50) | KIF11 | |
| SCHEMBL98804 | 0.81 | KIF11 (0.71) | KIF11 | |
| SCHEMBL8504228 | 0.81 | KIF11 (0.47) | KIF11 | |
| SCHEMBL9972416 | 0.80 | KIF11 (0.46) | KIF11 | |
| Hydrochloric Acid SCHEMBL28040656 | 0.80 | KIF11 (0.69) | KIF11 | |
| SCHEMBL25400195 | 0.79 | KIF11 (0.74) | KIF11 | |
| SCHEMBL4534194 | 0.79 | KIF11 (0.45) | KIF11 | |
| SCHEMBL9889271 | 0.79 | KIF11 (0.45) | KIF11 | |
| SCHEMBL5357811 | 0.78 | KIF11 (0.55) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516432-B1 | METHOXATIN DERIVATIVES | BERRY & ASSOCIATES INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8198290-B2 | Methoxatin derivatives | BERRY AND ASSOCIATES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110152526-A1 | METHOXATIN DERIVATIVES | BERRY AND ASSOCIATES, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152526-A1 | METHOXATIN DERIVATIVES | PNMT, XDH, PRDX1 | KIF11 4647/4885IDO1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.